Aminoglycoside Antibiotics Market Outlook, Trends And Future Opportunities (2024-2031)

Aminoglycoside Antibiotics Market Outlook, Trends And Future Opportunities (2024-2031)

Aminoglycoside Antibiotics Market, By Product Type (Amikacin, Gentamicin, Tobramycin, Neomycin, Streptomycin, Paromomycin, Others), By Route of Administration (Intravenous, Intramuscular, Topical, Inhalation, Others), By Application (Respiratory Tract Infections, Urinary Tract Infections, Septicemia, Endocarditis, Meningitis, Bone and Joint Infections, Others), By End-user (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, Others), By Spectrum of Activity (Broad-spectrum, Narrow-spectrum), By Mechanism of Action (Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, DNA/RNA Synthesis Inhibitors, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) The report offers a comprehensive view of the market from supply as well as demand side to help take informed decisions.

  • Published On: Jun 2024
  • Author(s): Sagar Karlekar
  • Report ID: IDA158
  • Region: Global
  • Format: PDF/EXCEL

Table Of Contents:

Chapter 1. Research Methodology and Scope

  • Market Segmentation and Scope
  • Regional Coverage
  • Objectives
  • Research Methodology

Chapter 2. Executive Summary

  • Market Landscape
  • Market Size & Forecast
  • Competitive Landscape

Chapter 3. Aminoglycoside Antibiotics Market: By Product Type Trends, Size, and Future Outlook

  • By Product Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Product Type Definitions, Technology Landscape
  • By Product Type Market Drivers
    • Product Launches
    • Technology Launches
  • By Product Type Market Restraints

Chapter 4. Aminoglycoside Antibiotics Market: By Route of Administration Trends, Size, and Future Outlook

  • By Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Route of Administration Definitions, Technology Landscape
  • By Route of Administration Market Drivers
    • Product Launches
    • Technology Launches
  • By Route of Administration Market Restraints

Chapter 5. Aminoglycoside Antibiotics Market: By Application Trends, Size, and Future Outlook

  • By Application Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Application Definitions, Technology Landscape
  • By Application Market Drivers
    • Product Launches
    • Technology Launches
  • By Application Market Restraints

Chapter 6. Aminoglycoside Antibiotics Market: By End-user Trends, Size, and Future Outlook

  • By End-user Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By End-user Definitions, Technology Landscape
  • By End-user Market Drivers
    • Product Launches
    • Technology Launches
  • By End-user Market Restraints

Chapter 7. Aminoglycoside Antibiotics Market: By Spectrum of Activity Trends, Size, and Future Outlook

  • By Spectrum of Activity Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Spectrum of Activity Definitions, Technology Landscape
  • By Spectrum of Activity Market Drivers
    • Product Launches
    • Technology Launches
  • By Spectrum of Activity Market Restraints

Chapter 8. Aminoglycoside Antibiotics Market: By Mechanism of Action Trends, Size, and Future Outlook

  • By Mechanism of Action Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Mechanism of Action Definitions, Technology Landscape
  • By Mechanism of Action Market Drivers
    • Product Launches
    • Technology Launches
  • By Mechanism of Action Market Restraints

Chapter 9. Aminoglycoside Antibiotics Market: By Distribution Channel Trends, Size, and Future Outlook

  • By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
  • By Distribution Channel Definitions, Technology Landscape
  • By Distribution Channel Market Drivers
    • Product Launches
    • Technology Launches
  • By Distribution Channel Market Restraints

Chapter 10. Aminoglycoside Antibiotics Market: Regional Market Trends, Size, and Future Outlook

  • North America
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
    • Market Size (US$), CAGR (%), and Forecast (2021-2031)
    • Definitions, Technology Landscape
    • Market Drivers
      • Product Launches
      • Technology Launches
      • [Write Any Such Market Drivers Based on previous information]
    • Market Restraints
    • Competitive Outlook
  • Europe
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
    • Market Size (US$), CAGR (%), and Forecast (2021-2031)
    • Definitions, Technology Landscape
    • Market Drivers
      • Product Launches
      • Technology Launches
      • [Write Any Such Market Drivers Based on previous information]
    • Market Restraints
    • Competitive Outlook
  • Asia Pacific
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
    • Market Size (US$), CAGR (%), and Forecast (2021-2031)
    • Definitions, Technology Landscape
    • Market Drivers
      • Product Launches
      • Technology Launches
      • [Write Any Such Market Drivers Based on previous information]
    • Market Restraints
    • Competitive Outlook
  • Latin America
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
    • Market Size (US$), CAGR (%), and Forecast (2021-2031)
    • Definitions, Technology Landscape
    • Market Drivers
      • Product Launches
      • Technology Launches
      • [Write Any Such Market Drivers Based on previous information]
    • Market Restraints
    • Competitive Outlook
  • Middle East, and Africa
    • Trends, Market Size (US$), CAGR (%), and Future Outlook
    • Market Size (US$), CAGR (%), and Forecast (2021-2031)
    • Definitions, Technology Landscape
    • Market Drivers
      • Product Launches
      • Technology Launches
      • [Write Any Such Market Drivers Based on previous information]
    • Market Restraints
    • Competitive Outlook

Chapter XYZ. Aminoglycoside Antibiotics Market: Competitive Landscape

  • Pfizer Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Novartis AG
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Sanofi
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Merck & Co., Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • GlaxoSmithKline plc
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Bayer AG
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Eli Lilly and Company
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Bristol-Myers Squibb Company
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • AbbVie Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Astellas Pharma Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Achaogen, Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Melinta Therapeutics, Inc.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Allergan plc
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Wockhardt Ltd.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Xellia Pharmaceuticals ApS
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Cipla Ltd.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Lupin Ltd.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Zydus Cadila
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies
  • Aurobindo Pharma Ltd.
    • Company Overview
    • Financial Outlook
    • Product Portfolio
    • Strategies

Research Methodology

  • Primary Research
  • Secondary Research
  • Assumptions
  • IDataAcumen Analysis
  • Paid Databases

Appendix

  • About Us

Frequently Asked Questions

The current market size of the Aminoglycoside Antibiotics industry is US$ 1.2 billion.

The key factors hampering the growth of the Aminoglycoside Antibiotics Market are: side effects concerns, stringent regulatory requirements, competition from alternative therapies, high development costs, limited pipeline, resistance development, dosing complexities, nephrotoxicity, ototoxicity, and supply chain disruptions.

The key factors driving the growth of the Aminoglycoside Antibiotics Market are: rising prevalence of bacterial infections, increasing antibiotic resistance, growing healthcare expenditure, aging population, advancements in diagnostic techniques, novel antibiotic development, and implementation of antibiotic stewardship programs.

The leading component segment in the Aminoglycoside Antibiotics Market is the amikacin segment, widely used for treating resistant bacterial infections.

The major players operating in the Aminoglycoside Antibiotics Market are Pfizer Inc., Novartis AG, Sanofi, Merck & Co., Inc., GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AbbVie Inc., Astellas Pharma Inc., Achaogen, Inc., Melinta Therapeutics, Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Wockhardt Ltd., Xellia Pharmaceuticals ApS, Cipla Ltd., Lupin Ltd., Zydus Cadila, and Aurobindo Pharma Ltd.

The North America region is expected to lead the Aminoglycoside Antibiotics Market, with a market share of 35.2% in 2023.

The key drivers of the Aminoglycoside Antibiotics Market are rising prevalence of bacterial infections, increasing antibiotic resistance, growing healthcare expenditure, aging population, advancements in diagnostic techniques, novel antibiotic development, and implementation of antibiotic stewardship programs.